RT Journal Article
SR Electronic
T1 Treatment of Squamous Cell Carcinoma of the Esophagus Synchronously Associated with Head and Neck Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 909
OP 916
VO 31
IS 5
A1 MORITA, MASARU
A1 EGASHIRA, AKINORI
A1 NAKAJI, YU
A1 KAGAWA, MASAKI
A1 SUGIYAMA, MASAHIKO
A1 YOSHIDA, DAISUKE
A1 OTA, MITSUHIKO
A1 IKEBE, MASAHIKO
A1 MASUDA, MUNEYUKI
A1 INOUE, YOJIRO
A1 KUNITAKE, NAONOBU
A1 TOH, YASUSHI
YR 2017
UL http://iv.iiarjournals.org/content/31/5/909.abstract
AB Background/Aim: The aim of this study was to clarify the treatment strategy for synchronous squamous cell carcinoma of the esophagus (ESCC) and head and neck cancer (HNC). Patients and Methods: Treatment outcomes of 91 patients with synchronous ESCC and HNC were evaluated. Thirty-eight patients received simultaneous definitive chemoradiotherapy (CRT) and 15 patients underwent simultaneous resection. Results: Among the patients who received simultaneous CRT, adverse events (grade 3-5) were recognized in 14 patients (40%), including one case of death due to aspiration pneumonia. Complete response was observed in 22 patients with ESCC (58%) and 19 patients with HNC (50%). The five-year survival rate was 44%. There were no in-hospital deaths after simultaneous resection; however, postoperative complications were recognized in 4 patients. The five-year OS was 70%. Conclusion: The treatment of synchronous ESCC and HNC must be decided by adopting a strategy that is appropriate for each case. Both simultaneous CRT and simultaneous resection are feasible and effective treatment options.